Press Releases
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022
Jun 10, 2022
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022
Jun 10, 2022
Imago BioSciences to Host Virtual Investor Event
Jun 06, 2022
Imago BioSciences to Participate in Upcoming Investor Conferences
May 16, 2022
Imago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business Updates
May 12, 2022
Displaying 1 - 5 of 60